|
Senior Scientist, Deputy Director, Clinical Epidemiology, Ottawa Hospital Research Institute
Head,
Thrombosis Program
Division of Hematology
Associate Professor
Dr. Marc Rodger, M.D., FRCP(C), MSc. is an Associate Professor in the Faculty of Medicine, Departments of Medicine, Obstetrics and Gynecology and Epidemiology and Community Medicine, the Head of the Thrombosis Program for the Division of Hematology, the Program Director for the Thrombosis Fellowship program and the Deputy Director of the Clinical Epidemiology Program at the Ottawa Hospital Research Institute.
Dr. Rodger received his M.D., M.Sc. (Clinical Epidemiology) from the University of Ottawa. He completed his residency in Internal Medicine and fellowships in Hematology and Thrombosis at the University of Ottawa.
He is a Heart and Stroke Foundation of Ontario Career Scientist.
RESEARCH INTERESTS
Dr. Rodger's clinical research program is focused on thrombophilia, thrombosis and pregnancy. Dr. Rodger's secondary research interests include studies that examine novel associations between thrombophilia and disease, diagnosis of pulmonary embolism, predictors of recurrent venous thromboembolism, cost effectiveness of interventions in thrombosis and thrombophilia and methodologic standards for evaluations of diagnostic tests.
RESEARCH ACTIVITIES (active Peer Reviewed Grants as Principal Investigator)
2006-2011
Thrombophilia in Pregnancy Prophylaxis Study (TIPPS)
(2.4 million over 5 years)
CIHR - MCT 82205
Principal Investigator
2006-2011
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism
(2,312,255 over 5 years)
CIHR - MCT 200509
Role Co-Principal Investigator
2006-2011
Ontario Early Researcher Award
Thrombophilia: Novel associations and therapeutic interventions
($100,000)
Role Principal Investigator
2005-2008
TAPP Thrombophilia and Placental Pathology
($123,849 over 3 years)
Heart and Stroke Foundation of Ontario - NA 5587
Principal Investigator
2003-2008
TIGRESS Thrombophilia and Intrauterine Growth Restriction Study
($1,036,544 over 5 years)
CIHR - MOP 64461
Role-Principal Investigator
Most Recent Publications (provided by The Ottawa Hospital Library database)
Le GG;Carrier M;Tierney S;Majeed H;Rodger M;Wells PS;, (2009 Oct 30), Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram- do we really need genotyping?, J Thromb Haemost, -> view abstract
Bourjeily G;Paidas M;Khalil H;Rosene-Montella K;Rodger M;, (2009 Nov 2), Pulmonary embolism in pregnancy, Lancet, -> view abstract
Carrier M;Righini M;Djurabi RK;Huisman MV;Perrier A;Wells PS;Rodger M;Wuillemin WA;Gal GL;, (2009 May), VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies, Thromb Haemost, Vol.101, Issue 5, 886-892 -> view abstract
Crowther MA;Ageno W;Garcia D;Wang L;Witt DM;Clark NP;Blostein MD;Kahn SR;Vesely SK;Schulman S;Kovacs MJ;Rodger MA;Wells P;Anderson D;Ginsberg J;Selby R;Siragusa S;Silingardi M;Dowd MB;Kearon C;, (2009 Mar 3), Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial, Ann Intern Med, Vol.150, Issue 5, 293-300 -> view abstract
Wells PS;Louzada ML;Taljaard M;Anderson DR;Kahn SR;Langlois NJ;Rutberg J;Kovacs MJ;Rodger MA;, (2009 Jun 3), A Pilot Study to Assess the Feasibility of a Multicenter Cluster Randomized Trial for the Management of Asymptomatic Persons with a Thrombophilia, J Genet Couns, -> view abstract
Dao V;Rodger M;, (2009 Jun 22), Anticoagulants to prevent placenta-mediated pregnancy complications: a review of current evidence, Curr Opin Hematol, -> view abstract
Chan WS;Lee A;Spencer FA;Crowther M;Rodger M;Ramsay T;Ginsberg JS;, (2009 Jul 21), Predicting deep venous thrombosis in pregnancy: out in 'LEFt' field?, Ann Intern Med, Vol.151, Issue 2, 85-92 -> view abstract
Lazo-Langner A;Rodger MA;, (2009 Jul), Overview of current venous thromboembolism protocols in hip reconstruction, Orthop Clin North Am, Vol.40, Issue 3, 427-436 -> view abstract
Carrier M;Le Gal G;Cho R;Tierney S;Rodger M;Lee AY;, (2009 Feb 25), Dose escalation of low molecular weight heparin to manage recurrent venous thromboemblic events despite systemic anticoagulation in cancer patients, J Thromb Haemost, -> view abstract
Le Gal G;Kovacs MJ;Carrier M;Do K;Kahn SR;Wells PS;Anderson DA;Chagnon I;Solymoss S;Crowther M;Righini M;Perrier A;White RH;Vickars L;Rodger M;, (2009 Feb 18), Validation of a diagnostic approach to exclude recurrent venous thromboembolism, J Thromb Haemost, -> view abstract
Oake N;van Walraven C;Rodger MA;Forster AJ;, (2009 Apr 28), Effect of an interactive voice response system on oral anticoagulant management, CMAJ, Vol.180, Issue 9, 927-933 -> view abstract
Educational Interests
Dr. Rodger is the Program Director for the Hematology residency training program, the Program Director for the Thrombosis fellowship program and a member of the graduate studies committee in the Department of Epidemiology and Community Medicine. His focus is on the development of training paths for academic clinicians in general and specifically in Hematology and Thrombosis. He is also actively involved in continuing education of community physicians and colleagues in our university and other Canadian universities presenting numerous rounds and educational conferences.
| |
General Campus
(see 
